Drug
Ibudilast clinical trials
Also written MN-166 and AV411.
- studies test it
- 21
- open now
- 1
- in phase 3
- 3
- first study started
- 2006
Keep track of what changes. Save the ibudilast studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
21 studies that test it; most in 2013 (4)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2011 | 2 |
| 2013 | 4 |
| 2014 | 1 |
| 2016 | 1 |
| 2018 | 4 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 15
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 12
MediciNova (8) · University of California, Los Angeles (5) · University of Pennsylvania (1) · University Health Network, Toronto (1) · VA Office of Research and Development (1) · New York State Psychiatric Institute (1) · Parisa Gazerani (1) · Avigen (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ibudilast is read from its arms, and is right about nine times in ten.
Testing it · 21
- Regeneration in Cervical Degenerative MyelopathyRecruitingPhase 3Cambridge University Hospitals NHS Foundation TrustNCT04631471Written as Ibudilast
- Ibudilast for Treating Alcohol Use DisorderActive, not recruitingPhase 2University of PennsylvaniaNCT05414240Written as Ibudilast
- Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALSActive, not recruitingPhase 2/3MediciNovaNCT04057898Written as MN-166
- RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative MedicineCompletedPhase 2/3University Health Network, TorontoNCT05513560Written as Ibudilast
- Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine UsersCompletedPhase 2VA Office of Research and DevelopmentNCT03341078Written as Ibudilast
- Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent GlioblastomaCompletedPhase 1/2MediciNovaNCT03782415Written as MN-166
- Ibudilast for the Treatment of Alcohol Use DisorderCompletedPhase 2University of California, Los AngelesNCT03594435Written as Ibudilast
- Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDSCompletedPhase 2MediciNovaNCT04429555Written as Ibudilast
- A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)CompletedPhase 1/2MediciNovaNCT02714036Written as ibudilast
- Safety Interaction Trial Ibudilast and MethamphetamineCompletedPhase 1University of California, Los AngelesNCT01217970Written as Ibudilast 20mg
- Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)CompletedPhase 2MediciNovaNCT02238626Written as MN-166
- Ibudilast and Withdrawal-Related DysphoriaCompletedPhase 2University of California, Los AngelesNCT03489850Written as Ibudilast
- Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple SclerosisCompletedPhase 2MediciNovaNCT01982942Written as ibudilast
- Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy VolunteersCompletedPhase 1MediciNovaNCT04054206Written as MN-166
- Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy VolunteersCompletedPhase 1MediciNovaNCT03533387Written as MN-166
- Trial of Ibudilast for Methamphetamine DependenceCompletedPhase 2University of California, Los AngelesNCT01860807Written as Ibudilast
- Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid WithdrawalCompletedPhase 2New York State Psychiatric InstituteNCT00723177Written as AV411
- Development of Ibudilast for Alcohol Use DisorderCompletedPhase 1University of California, Los AngelesNCT02025998Written as Ibudilast
- Ibudilast in the Treatment of Patients With Chronic Migraine.CompletedPhase 1Parisa GazeraniNCT01389193Written as Ibudilast
- Ibudilast in the Treatment of Medication Overuse HeadacheStatus unknownPhase 1/2University of AdelaideNCT01317992Written as Ibudilast
Codes
What other systems call ibudilast · ClinicalTrials.gg INT003095
- MeSH (NLM) C038366ibudilastConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) M0TTH61XC5IBUDILASTConfirmed FDA, NLM, Wikidata
- Wikidata Q261167ibudilastConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C65876IbudilastOne source FDA
- DrugBank DB05266One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C038366 | ibudilast | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | M0TTH61XC5 | IBUDILAST | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q261167 | ibudilast | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C65876 | Ibudilast | One source FDA |
| DrugBank | DB05266 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.